Relyea Zuckerberg Hanson LLC Has $930,000 Stock Position in Stryker Co. (NYSE:SYK)

Relyea Zuckerberg Hanson LLC boosted its holdings in Stryker Co. (NYSE:SYK) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,583 shares of the medical technology company’s stock after buying an additional 91 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Stryker were worth $930,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Dunhill Financial LLC lifted its stake in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Centennial Bank AR increased its position in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Stryker in the third quarter valued at approximately $36,000. Hara Capital LLC acquired a new position in shares of Stryker during the 3rd quarter worth approximately $42,000. Finally, HBW Advisory Services LLC bought a new stake in shares of Stryker during the 3rd quarter worth approximately $42,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.50% of the company’s stock.

Stryker Price Performance

Shares of SYK traded up $0.11 during midday trading on Friday, hitting $381.90. The company’s stock had a trading volume of 320,922 shares, compared to its average volume of 1,239,618. Stryker Co. has a one year low of $307.23 and a one year high of $398.20. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The company’s fifty day simple moving average is $375.12 and its two-hundred day simple moving average is $358.32. The stock has a market capitalization of $145.59 billion, a price-to-earnings ratio of 40.96, a price-to-earnings-growth ratio of 2.51 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same period last year, the company posted $2.46 EPS. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Tuesday, January 7th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Canaccord Genuity Group boosted their price target on Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Citigroup raised their price objective on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $425.00 price target on shares of Stryker in a research note on Tuesday, January 7th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.